Gonadorelin

Gonadorelin (also known as Gonadorelina, GnRH-I, Gonadorelinum, Fertagyl) is a anti-aging research peptide. Gonadorelin is a synthetic decapeptide that functions as a gonadotropin-releasing hormone (GnRH) receptor agonist. It is used in medicine to stimulate the release of gonadotropins.

Gonadorelin, also known as GnRH-I, is a synthetic form of gonadotropin-releasing hormone. It acts as an agonist at the gonadotropin-releasing hormone receptor, stimulating the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This mechanism makes it useful for various reproductive and endocrine conditions. Gonadorelin has been studied for its applications in infertility, prostatic neoplasms, hypogonadism, and breast neoplasms, reaching Phase 3 clinical trials for these indications. It is an FDA-approved compound, first approved in 1989. Research also explores its potential in conditions like Kallmann Syndrome and Polycystic Ovary Syndrome, and systematic reviews have investigated its use in endometriosis, menorrhagia, and breast pain.

1 Mechanism of action

Gonadotropin-releasing hormone receptor agonist (agonist)

Primary targets: Gonadotropin-releasing hormone receptor

2 Reported effects

Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.

2.1 Indicated / studied for

• Infertility
• Prostatic Neoplasms
• Hypogonadism
• Breast Neoplasms
• Prostatic Neoplasms, Castration-Resistant
• Kallmann Syndrome
• Paget Disease, Extramammary
• Polycystic Ovary Syndrome

3 Chemical and physical properties

3.1 Amino acid sequence

4 Research studies (8)

1. Endometriosis
   BMJ clinical evidence (2007) · Systematic Review
2. Menorrhagia
   BMJ clinical evidence (2012) · Systematic Review
3. Endometriosis
   BMJ clinical evidence (2010) · Systematic Review
4. Menorrhagia
   BMJ clinical evidence (2008) · Systematic Review
5. Breast pain
   BMJ clinical evidence (2011) · Systematic Review
6. Premenstrual syndrome
   BMJ clinical evidence (2007) · Systematic Review
7. Breast pain
   BMJ clinical evidence (2007) · Systematic Review
8. Bleeding associated with uterine leiomyomas. Tailor treatment to the individual patient
   Prescrire international (2014) · Review

5 Safety and risk profile

5.1 Regulatory status

Gonadorelin is currently classified as FDA approved. Approval applies to specific clinical indications and dosing; research-grade material is not the approved product.

6 Frequently asked questions

What is Gonadorelin used for?

Gonadorelin is used for various conditions related to reproductive and endocrine health. It has been studied and reached Phase 3 clinical trials for infertility, prostatic neoplasms, hypogonadism, and breast neoplasms. It is also explored for conditions such as Kallmann Syndrome and Polycystic Ovary Syndrome.

How does Gonadorelin work?

Gonadorelin functions as an agonist for the gonadotropin-releasing hormone (GnRH) receptor. By binding to this receptor, it stimulates the pituitary gland to release gonadotropins, specifically luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which are crucial for reproductive function.

Is Gonadorelin FDA approved?

Yes, Gonadorelin is an FDA-approved compound. It received its first approval in 1989, indicating its established use in clinical practice for specific indications.

What is Gonadorelin derived from?

Gonadorelin is a synthetic decapeptide, meaning it is a man-made compound composed of ten amino acids. It is designed to mimic the natural gonadotropin-releasing hormone produced in the body.

7 References

1. Gonadorelin — compound summary PubChem. View source
2. Gonadorelin — molecule record ChEMBL. View source
3. Gonadorelin — published literature (295 records) PubMed. View source

8 See also

• Peptide encyclopedia index
• Peptide reconstitution calculator
• Glossary of peptide research terms